Increased expression of uPA, uPAR, and PAI-1 in psoriatic skin and in basal cell carcinomas

Archives of Dermatological Research

Volumn 309, Issue 6, 2017, Pages 433-442

  Rubina, K A ^a   Sysoeva, V Yu ^a   Zagorujko, E I ^b   Tsokolaeva, Z I ^b   Kurdina, M I ^a   Parfyonova, Ye V ^b   Tkachuk, V A ^a,b  

^a MOSCOW STATE UNIVERSITY   (Russian Federation)

^b INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

Author keywords

Basal cell carcinoma; Psoriasis; Urokinase; Urokinase receptor

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE; UROKINASE RECEPTOR; MEMBRANE PROTEIN; PLAT PROTEIN, HUMAN; PLAU PROTEIN, HUMAN; PLAUR PROTEIN, HUMAN; SERPINE1 PROTEIN, HUMAN; TISSUE PLASMINOGEN ACTIVATOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CARCINOMA CELL; CELL INVASION; CELL PROLIFERATION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; EPIDERMIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS VULGARIS; SKIN BIOPSY; BIOPSY; CYTOLOGY; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; NORMAL HUMAN; PATHOLOGY; PSORIASIS; SKIN; SKIN TUMOR; STROMA CELL; TUMOR INVASION; UPREGULATION;

ADULT; BIOMARKERS, TUMOR; BIOPSY; CARCINOMA, BASAL CELL; HEALTHY VOLUNTEERS; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM INVASIVENESS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PSORIASIS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SKIN; SKIN NEOPLASMS; STROMAL CELLS; TISSUE PLASMINOGEN ACTIVATOR; UP-REGULATION;

EID: 85018510367     PISSN: 03403696     EISSN: 1432069X     Source Type: Journal    
DOI: 10.1007/s00403-017-1738-z     Document Type: Article

References (71)

1. Al-Horani RA (2014) Serpin regulation of fibrinolytic system; implications for applications in cardiovascular diseases. Cardiovasc Hematol Agents Med Chem 12(2):91–125
2. Andreasen PA, Kjoller L, Christensen L, Duffy MJ (1997) The urokinase-type plasminogen activation system in cancer metastasis; a review. Int J Cancer 72:1–22
3. Barker JNWN (1991) Pathophysiology of psoriasis. Lancet 338:227–230
4. Bhushan M, Mclaughlin B, Weiss JB (1999) Level of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol 141:1054–1060
5. Blasi F, Vassalli J-D, Dano K (1987) Urokinase-type plasminogen activator; proenzyme, receptor, and inhibitors. J Cell Biol 104:801–804
6. Blasi F, Carmeliet P (2002) uPAR; a versatile signaling orchestrator. Nat Rev Mol Cell Biol 3:932–943
7. Blasi F, Sidenius N (2010) The urokinase receptor; focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett 584(9):1923–1930
8. Buo L, Meling GI, Karlsrud TS (1995) Antigen level of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness. Hum Pathol 26:1133–1138
9. Chen CS, Jensen PJ (1996) Serum is a potent stimulator of keratinocyte tissue plasminogen activator expression. J Investig Dermatol 106(2):238–242
10. Choi J, Koo JY (2003) Quality of life issues in psoriasis. J Am Acad Dermatol 49:57–61
11. Collen D (1999) The plasminogen (fibrinolytic) system. Thromb Haemost 82(2):259–270
12. Collen D (2001) Role of the plasminogen system in fibrin-homeostasis and tissue remodelling. Hematology 1(1):1–9
13. Colman RW, Wu Y, Liu Y (2010) Mechanisms by which cleaved kininogen inhibits endothelial cell differentiation and signaling. Thromb Haemost 104:875–885
14. Creamer D, Allen M, Sousa A (1995) Altered vascular endothelium integrin expression in psoriasis. Am J Pathol 147:1661–1667
15. Creamer D, Jaggar M, Allen M (1997) Overexpression of angiogenic growth factor platelet-derived endothelial cell growth factor/thymidine phosphorylase in psoriatic epidermis. Br J Dermatol 137:8851–8855
16. Creamer D, Sullivan D, Bicknell R, Barker J (2002) Angiogenesis in psoriasis. Angiogenesis 5:231–236
17. Detmar M, Brown LF, Claffey KP (1994) Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptor in psoriasis. J Exp Med 180:1141–1146
18. Duffy MJ, McGowan PM, Harbeck N, Thomssen C, Schmitt M (2014) uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies. Breast Cancer Res 16(4):428
19. Elder JT, Fisher GJ, Lindquist PB (1989) Overexpression of transforming growth factor-a in psoriatic epidermis. Science 243:811–814
20. Ettehadi P, Greaves MW, Wallach D (1994) Elevated tumor necrosis factor-a (TNF-a) biological activity in psoriatic lesions. Clin Exp Immunol 96:146–151
21. Feller L, Khammissa RA, Kramer B, Altini M, Lemmer J (2016) Basal cell carcinoma, squamous cell carcinoma and melanoma of the head and face. Head Face Med 12:11
22. Fraki JE, Lazarus GS, Gilgor RS, Marchase P, Singer KH (1983) Correlation of epidermal plasminogen activator activity with disease activity in psoriasis. Br J Dermatol 108:39–44
23. Ganzetti G, Campanati A, Molinelli E, Offidani A (2016) Psoriasis, non-alcoholic fatty liver disease, and cardiovascular disease: three different diseases on a unique background. World J Cardiol 8(2):120–131
24. Gilhar A, David M, Kalish RS, Weisinger G (1996) In vivo effects of cytokines on psoriatic skin grafted on nude mice; involvement of the tumour necrosis factor (TNF) receptor. Clin Exp Immunol 106(1):134–142
25. Gissler HM, Frank R, Kramer MD (1993) Immunohistochemical characterization of the plasminogen activator system in psoriatic epidermis. Br J Dermatol 128(6):612–618
26. Godi A (2004) New approaches to psoriasis treatment. Acta Dermatovenerol 13(2):50–57
27. Gramling MW, Church FC (2010) Plasminogen activator inhibitor-1 is an aggregate response factor with pleiotropic effects on cell signaling in vascular disease and the tumor microenvironment. Thromb Res 125:377–381
28. Grondahl-Hansen J, Nielsen LS, Kristensen P, Grondahl-Hansen V, Andreasen PA, Dano K (1985) Plasminogen activator in psoriatic scales is of the tissue-type PA as identified by monoclonal antibodies. Br J Dermatol 113(3):257–263
29. Grondahl-Hansen J, Ralfkiaer E, Nielsen LS, Kristensen P, Frentz G, Dano K (1987) Immunohistochemical localization of urokinase- and tissue-type plasminogen activators in psoriatic skin. J Investig Dermatol 88(1):28–32
30. Harbeck N, Kates RE, Schmitt M (2004) Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin Breast Cancer 5(5):348–352
31. Heissig B, Dhahri D, Eiamboonsert S, Salama Y, Shimazu H, Munakata S, Hattori K (2015) Role of mesenchymal stem cell-derived fibrinolytic factor in tissue regeneration and cancer progression. Cell Mol Life Sci 72(24):4759–4770
32. Hildenbrand R, Schaaf A (2009) The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion. Int J Oncol 34(1):15–23
33. Hohler T, Marker-Hermann E (2001) Psoriatic arthritis; clinical aspects, genetics and the role of T-cells. Curr Opin Rheumatol 13:273–279
34. Jensen PJ, Baird J, Morioka S, Lessin S, Lazarus GS (1988) Epidermal plasminogen activator is abnormal in cutaneous lesions. J Investig Dermatol 90(6):777–782
35. Jensen PJ, Baird J, Belin D, Vassalli JD, Busso N, Gubler P, Lazarus GS (1990) Tissue plasminogen activator in psoriasis. J Investig Dermatol 95(5):13–14
36. Kauvar AN, Cronin T Jr, Roenigk R, Hruza G, Bennett R (2015) Consensus for nonmelanoma skin cancer treatment: basal cell carcinoma, including a cost analysis of treatment methods. Dermatol Surg 41(5):550–571
37. Kuroda K, Sapadin A, Shoji T (2001) Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis. J Investig Dermatol 116:713–720
38. Lanoue J, Goldenberg G (2016) Basal cell carcinoma: a comprehensive review of existing and emerging nonsurgical therapies. J Clin Aesthet Dermatol 9(5):26–36
39. Leurer C, Rabbani SA (2015) Plasminogen activator system—diagnostic, prognostic and therapeutic implications in breast cancer, a concise review of molecular pathology of breast cancer. In: Gunduz M (ed) A concise review of molecular pathology of breast cancer. ISBN 978-953-51-2030-8
40. Lomas A, Leonardi-Bee J, Bath-Hextall F (2012) A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol 166(5):1069–1080
41. Lotti T, Bonan P, Panconesi E (1989) Plasminogen activation in psoriasis. Acta Derm Venereol Suppl (Stockh) 146:36–38
42. Lotti T, Bonan P, Cannarozzo G, Fedi AM, Panconesi E (1990) Antipsoriatic therapies inhibit epidermal plasminogen activator activity. Int J Dermatol 29(7):528–530
43. Lupu M, Caruntu C, Ghita MA, Voiculescu V, Voiculescu S, Rosca AE, Caruntu A, Moraru L, Popa IM, Calenic B, Greabu M, Costea DE (2016) Gene expression and proteome analysis as sources of biomarkers in basal cell carcinoma. Dis Mark. doi:10.1155/2016/9831237
44. Lyons-Giordano B, Loskutoff D, Chen CS, Lazarus G, Keeton M, Jensen PJ (1994) Expression of plasminogen activator inhibitor type 2 in normal and psoriatic epidermis. Histochemistry 101(2):105–112
45. Maguire T, Chin D, Soutar D, Duffy MJ (2000) Low levels of urokinase plasminogen activator components in basal cell carcinoma of the skin. Int J Cancer 85:457–459
46. Mazar AP, Henkin J, Goldfarb RH (1999) The urokinase plasminogen activator system in cancer; implication for tumor angiogenesis and metastasis. Angiogenesis 3:15–32
47. Mazzieri R, Pietrogrande G, Gerasi L, Gandelli A, Colombo P, Moi D, Brombin C, Ambrosi A, Danese S, Mignatti P, Blasi F, D’Alessio S (2015) Urokinase receptor promotes skin tumor formation by preventing epithelial cell activation of notch. Cancer Res 75(22):4895–4909
48. Miller SJ, Jensen PJ, Dzubow LM, Lazarus GS (1992) Urokinase plasminogen activator is immunocytochemically detectable in squamous cell but not basal cell carcinomas. J Investig Dermatol 98(3):351–358
49. Nagy B, Ban J, Brdar B (1977) Fibrinolysis associated with human neoplasia; production of plasminogen activators by human tumors. Int J Cancer 19:614–620
50. Nickoloff BJ, Mitra RS, Varani J (1994) Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. Am J Pathol 144:820–828
51. Nickoloff BJ (2000) Characterization of lymphocyte-dependent angiogenesis using a SCID mouse; Human skin model of psoriasis. J Investig Dermatol 5:67–73
52. Nielsen HJ, Christensen IJ, Svendsen MN, Hansen U, Werther K, Brunner N, Petersen LJ, Kristensen JK (2002) Elevated plasma levels of vascular endothelial growth factor and plasminogen activator inhibitor-1 decrease during improvement of psoriasis. Inflamm Res 51(11):563–567
53. Parfyonova YV, Plekhanova OS, Tkachuk VA (2002) Plasminogen activators in vascular remodeling and angiogenesis. Biochemistry (Moscow) 67(1):139–156
54. Plekhanova OS, Parfenova EV, Tkachuk VA (2015) Mechanisms of vascular remodeling following arterial injury. Kardiologiia 55(7):63–77
55. Quinn AG, Perkins W (2010) Non-melanoma skin cancer and other epidermal skin tumors. In: Burns T, Breathnach S, Cox N, Griffiths C (eds) Rook’s textbook of dermatology. Blackwell Publishing Ltd, Chichester
56. Rogers HW, Weinstock MA, Feldman SR, Coldiron BM (2012) Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the US population. JAMA Dermatol 151(10):1081–1086
57. Rox JM, Reinartz J, Kramer MD (1996) Interleukin-1 beta upregulates tissue-type plasminogen activator in a keratinocyte cell line (HaCaT). Arch Dermatol Res 288(9):554–558
58. Ruano J, Suárez-Fariñas M, Shemer A, Oliva M, Guttman-Yassky E, Krueger JG (2016) Molecular and cellular profiling of scalp psoriasis reveals differences and similarities compared to skin psoriasis. PloS One 11(2):1–18
59. Santibanez JF (2013) Transforming growth factor-beta and urokinase-type plasminogen activator; dangerous partners in tumorigenesis. implications in skin cancer volume. Hindawi Publishing Corporation, UK, ISRN Dermatology. Article ID 597927
60. Sappino AP, Belin D, Huarte J, Hirschel-Scholz S, Saurat JH, Vassalli JD (1991) Differential protease expression by cutaneous squamous and basal cell carcinomas. J Clin Investig 88(4):1073–1079
61. Schmitt M, Harbeck N, Thompson C (1997) Clinical impact of the plasminogen activation system in tumor invasion and metastasis; prognostic relevance and target for therapy. Thromb Hemost 78(1):285–296
62. Schmitt M, Mengele K, Napieralski R, Magdolen V, Reuning U, Gkazepis A (2010) Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn 10(8):1051–1067
63. Seetoo DQ, Crowe PJ, Russell PJ, Yang JL (2003) Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer. J Surg Oncol 82(3):184–193
64. Spiers EM, Lazarus GS, Lyons-Giordano B (1994) Expression of plasminogen activator enzymes in psoriatic epidermis. J Investig Dermatol 102(3):333–338
65. Spiers EM, Lazarus GS, Lyons-Giordano B (1996) Expression of plasminogen activators in basal cell carcinoma. J Pathol 178:290–296
66. Teofoli P, Mancini A, Lotti T (1996) Cyclosporine A inhibits tPA mRNA transcription in A431 cell line. Skin Pharmacol 9(2):137–140
67. Tkachuk VA, Plekhanova OS, Beloglazova IB, Parfenova EV (2013) A role of multi-domain structure of urokinase in regulating vascular growth and remodeling. Ukr Biokhim Zh 85:18–45
68. Tsuboi R, Yamaguchi T, Kurita Y, Nakao H, Ishihara K (1988) Comparison of proteinase activities in squamous cell carcinoma, basal cell epithelioma, and seborrheic keratosis. J Investig Dermatol 90:869–872
69. Tutrone WD, Saini R, Weinberg JM (2004) Biological therapy for psoriasis; an overview of infliximab, etanercept, efalizumab and alefacept. I Drugs 7(1):45–49
70. Vassalli J-D (1994) The urokinase receptor. Fibrinolysis 8(1):172–181
71. Zhang Y, Kenny HA, Swindell EP, Mitra AK, Hankins PL, Ahn RW, Gwin K, Mazar AP, O’Halloran TV, Lengyel E (2013) Urokinase plasminogen activator system-targeted delivery of nanobins as a novel ovarian cancer therapy. Mol Cancer Ther 12(12):2628–2639